about
Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical ImplicationsTranscription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) GeneTelomerase: The Devil InsideMulti-OMICs and Genome Editing Perspectives on Liver Cancer Signaling NetworksRoles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapiesTelomere and Telomerase Therapeutics in CancerHuman Specific Regulation of the Telomerase Reverse Transcriptase GeneThe dark matter of the cancer genome: aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutationsReactivation of telomerase in cancerTERT promoter mutations in thyroid cancerThe search for cis-regulatory driver mutations in cancer genomesTime to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaPersonalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterationsBRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrenceDiagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.Telomerase Activation in Hematological MalignanciesGenetic alterations in hepatocellular carcinoma: An updateORegAnno 3.0: a community-driven resource for curated regulatory annotationFunctional evaluation of TERT-CLPTM1L genetic variants associated with susceptibility of papillary thyroid carcinomaTERT promoter mutations: a novel independent prognostic factor in primary glioblastomasCancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancersA novel two-step genome editing strategy with CRISPR-Cas9 provides new insights into telomerase action and TERT gene expression.Genome-wide prediction of cancer driver genes based on SNP and cancer SNV dataCancer somatic mutations cluster in a subset of regulatory sites predicted from the ENCODE dataGlobal inference of disease-causing single nucleotide variants from exome sequencing dataTERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entitiesTelomere biology and translational research.Molecular Signature of Indeterminate Thyroid Lesions: Current Methods to Improve Fine Needle Aspiration Cytology (FNAC) Diagnosis.TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomasThe activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumorsTERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.SDHD promoter mutations are rare events in cutaneous melanomas but SDHD protein expression is downregulated in advanced cutaneous melanomaExpression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma.Melanoma genetics.Landscape of somatic mutations in 560 breast cancer whole-genome sequences.Diverse modes of genomic alteration in hepatocellular carcinoma
P2860
Q26738705-9C285A5B-4D20-4350-B0C7-2C7B5EE75AA4Q26739925-62F41E88-AAD8-46EC-AADE-E08E75539D13Q26739948-24FAB721-3FC0-40F2-92D7-08D7AE573960Q26741086-F12115DD-3242-4985-8911-C9C80583BBD8Q26744271-A8B11CB5-4427-44B4-B7B9-52D3363FAF70Q26744808-FD78C5C0-1D04-4492-9329-7650E0EF271AQ26745549-2A30C406-5638-4CFE-897B-EEE3CB789C9BQ26753387-76692261-E079-4061-9146-45E8F5608201Q26769014-8E7DBBA0-B5F2-486F-BB48-7044B01F8726Q26770808-BDBD83A4-2D6E-430A-BA53-F5059A39CC2EQ26781886-15C8F404-3C4B-406F-97CA-CEFCABA6DDB1Q26853261-46520284-4F32-4AE7-9862-3AD66103188FQ27027491-665594B2-FCCF-4839-9D3F-FF9ED69498BBQ27853042-A1C9DE20-3FBF-400B-A616-DD4831EBF208Q27853057-828B2645-DBE8-4EC8-B222-F86645195CDAQ27853068-62E6FB99-160F-48D9-9B01-258C22EB022BQ28068238-919D1907-168B-4A2E-8879-2E5F8E826208Q28073241-06C6EA5F-F23E-445B-BBDD-57C9946DE4EBQ28269966-5DB2EA82-9853-46E6-9750-6293B7448831Q28394370-02259D01-9D49-43E6-9961-21305FD65709Q28397245-827CD151-B8DE-4CC5-B2BF-1F0DFE51E823Q30459452-47F7D45E-2360-4A4F-AAE1-48711B5F0675Q30459839-C93D51DA-08AB-4D8D-90CF-74D9DC96E8FDQ30459853-7ED02F9D-5012-4260-AC49-DA6C8763C45DQ30838341-F8270AF6-33E5-4B84-A445-3139CDB4BD99Q31144723-1AEDAB43-1F23-4020-96DB-090E6B34AB23Q31159221-26219ED4-10C5-40F9-BADC-F492E5C59ACAQ33414576-86FC0614-B300-49D0-B882-B2CCD39CB956Q33613946-5EF1E26A-4F1B-4E7F-BA04-8C1471091537Q33624558-D3A949C5-9744-4F80-8FFD-A816672012C6Q33682388-49E6D313-B871-4E7A-AF9D-5734BBFFBD9DQ33688439-7717D9B8-3687-416A-B6EC-7EB59DD94295Q33688915-C071BF12-F7FF-405E-B482-8A34BC425856Q33709979-97356143-A674-4CA2-A261-255D624E12B5Q33769095-DEDF1F0D-CF99-4BF8-9B42-9B27BC473C7EQ33853615-DF0156C0-5BB2-4CAA-B4BB-8EBEF3A00A1DQ33917659-CF633745-9FDE-4997-BD55-119A47E49600Q34044830-51367E6F-FC6B-43BB-898C-1B09458FFCA8Q34046731-3F628093-F1EC-4E9B-B454-A824F3DA5686Q34306010-9D41B358-6B47-4029-A547-C0A4820AE818
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Frequency of TERT promoter mutations in human cancers.
@en
Frequency of TERT promoter mutations in human cancers.
@nl
type
label
Frequency of TERT promoter mutations in human cancers.
@en
Frequency of TERT promoter mutations in human cancers.
@nl
prefLabel
Frequency of TERT promoter mutations in human cancers.
@en
Frequency of TERT promoter mutations in human cancers.
@nl
P2093
P50
P356
P1476
Frequency of TERT promoter mutations in human cancers.
@en
P2093
Adriana Gaspar da Rocha
Ana Almeida
Fernando Pardal
Helena Pópulo
Joana Lyra
Jorge Lima
José Cameselle-Teijeiro
José Manuel Lopes
Ligia Castro
P2888
P356
10.1038/NCOMMS3185
P407
P577
2013-01-01T00:00:00Z